The directors present the strategic report for the year ended 31 December 2025.
Details of the group's performance for the financial year are set out in detail on page 9.
Turnover decreased year on year from £19,975,127 to £17,659,531, representing an 11.6% decrease, largely reflecting the disposal of Launch Diagnostics France SAS in September 2025 and the cessation of Launch Diagnostics Deutschland GmbH, both presented as discontinued operations in the year.
Gross margin increased from 42.8% to 44.8%, reflecting a change in the group's revenue mix following the disposal and cessation of the discontinued operations, which historically traded at a lower gross margin than the continuing UK business.
The group balance sheet on page 10 shows the group's net asset position of £7,728,425 at the year end, a decrease from £8,001,752, mainly driven by the loss for the year and the disposal of Launch Diagnostics France SAS.
Loss after tax for the year was £314,288, compared to a profit of £632 in 2024, mainly due to the trading loss of the discontinued operations and the loss on disposal of Launch Diagnostics France SAS.
The cash balance decreased from £3,563,227 to £1,319,405, mainly reflecting cash absorbed by operations in the year, the elimination of Launch Diagnostics France SAS's cash balances on disposal, and surplus funds also supporting the Group's wider cash pooling arrangements of the ultimate controlling party.
The Directors and management team continually monitor the key risks facing the company together with assessing the controls used for managing these risks. The principal risks and uncertainties facing the company are as follows:
Customer relationships - The company sells goods and services to the NHS. This government department, like many others, is under financial pressure and subject to budget constraints. Whilst it remains a stable business environment to operate in, a large portion of the company's income is reliant on NHS business. There is, however, no notable reduction in trade with NHS bodies, nor is there any such reduction forecast in coming years.
Change of ownership - The recent change of ownership may create some uncertainty as the business adjusts to new structures and priorities. The Board is monitoring the transition to ensure continuity of operations and to manage any potential risks arising during this period.
Supplier relationships - As a distribution company, the relationship with its manufacturing partners is a key factor for continued success. Expiry of these agreements without renewal is a risk, as is the acquisition of the manufacturer.
Product portfolio - The company acknowledges that the diagnostic reagent and instrumentation market is rapidly evolving through scientific and technological advances. It is key for the company to adapt to these changes in the market. The company seeks to provide a market leading service to customers by partnering with key suppliers, using the latest technologies and innovative emerging products.
Foreign trade - Trading with overseas suppliers exposes the company to the risk of adverse movements in foreign currency, as well as potential changes to tariffs and VAT, following Brexit, both impacting profit. The company mitigates this risk by close control and management of the cash and currency positions.
Key personnel - A potential risk is the loss of key personnel in the company. Management seeks to ensure that key personnel are appropriately remunerated to ensure that good performance is recognised.
Cybersecurity - Unexpected events such as failures of IT systems or the increasing threat of targeted cyber-attacks could disrupt the Company’s operations from any of its sites or lead to a loss of data. The Company continues to place reliance on third-party cloud-hosted applications, which provide cost-effective services with significant redundancies and disaster prevention and recovery strategies.
The Company has in place disaster recovery plans which are periodically tested and third-party specialists are used to assess any potential vulnerabilities in the Company’s systems. The Company ensures that all software and systems are regularly updated to latest software versions and firmware updates. Its cyber security plans are reviewed on a regular basis and recently upgraded security access levels have been established.
Loss of facilities - Should the Company’s facilities become inaccessible through damage caused by fire, flooding or theft, the ability to receive goods from suppliers and carry on meeting customer delivery timelines may be affected depending on the severity of the incident. The Company has established business continuity plans in place for each location which are regularly reviewed and tested. Resilience exists between sites so that certain operations could be quickly transferred from one facility to another where appropriate. Health and safety procedures and policies exist for each site with routine checks on facilities, equipment and infrastructure. The Company also maintains adequate insurance to cover any business damage or interruption.
The company manages its business using the following indicators:
Sales – the performance of the core product portfolio, discussed on page 1.
Gross margin – there has been an increase from 42.8% in 2024 to 44.8% in 2025.
Profit after tax - there has been a decrease from a profit of £632 in 2024 to a loss of £314,288 in 2025
The directors aim to maintain the focus on meeting customer demands and requirements and identifying opportunities to expand its product portfolio and continue sales growth.
At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The Directors have assessed the continued impact of challenging macro-economic factors on the business, preparing budgets and cash flow forecasts to determine its ability to meet debts as and when they fall due. In preparing these forecasts, the Directors have considered the current and future economic conditions that are expected to prevail over the period. The forecasts also include assumptions regarding the timing of expected cashflows in the future.
Based on the analysis performed management concluded that the company has adequate financial resources to continue operating as a going concern for a period of at least 12 months from the date of approval of these financial statements, the directors of Launch Diagnostics Holdings Limited therefore consider it appropriate to prepare the accounts on a going concern basis.
The forecasts prepared by management include growth in revenue from 2025 to 2026 and 2027 from new and existing contracts. The company expects to maintain a profit position and generate positive cashflows which will allow the company to focus on strategy into the longer term. Management has also modelled a downside scenario assuming no revenue growth in 2027 and this shows a continued profit position with positive cashflows.
Based on the analysis performed together with the available cashflows, the directors assess the company will have sufficient funds to meet its liabilities as they fall due. As a result of this assessment, the Directors have adopted the going concern basis of accounting for the preparation of these financial statements.
On behalf of the board
The directors present their annual report and financial statements for the year ended 31 December 2025.
The results for the year are set out on page 9.
Ordinary dividends were paid amounting to £nil (2024: £nil).
The directors who held office during the year and up to the date of signature of the financial statements were as follows:
Saffery LLP were appointed as auditor to the company and in accordance with section 485 of the Companies Act 2006, have expressed their willingness to continue in office.
United Kingdom company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the group and parent company financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the group and parent company, and of the profit or loss of the group for that period.
In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and accounting estimates that are reasonable and prudent;
state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the group and parent company will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group’s and parent company’s transactions and disclose with reasonable accuracy at any time the financial position of the group and parent company, and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and parent company, and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The directors have assessed the company's ability to continue as a going concern and have prepared forecasts and cash flow projections for a period of at least twelve months from the date of approval of these financial statements. In making this assessment, the directors have considered the current economic environment, the company's anticipated trading performance, available cash resources, and its ability to meet liabilities as they fall due. Based on this assessment, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Accordingly, the financial statements have been prepared on the going concern basis.
We have audited the financial statements of Launch Diagnostics Holdings Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2025 which comprise the group statement of comprehensive income, the group balance sheet, the company balance sheet, the group statement of changes in equity, the company statement of changes in equity, the group statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).
Basis for opinion
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
Other information
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud are detailed below.
Identifying and assessing risks related to irregularities:
We assessed the susceptibility of the group and parent company’s financial statements to material misstatement and how fraud might occur, including through discussions with the directors, discussions within our audit team planning meeting, updating our record of internal controls and ensuring these controls operated as intended. We evaluated possible incentives and opportunities for fraudulent manipulation of the financial statements. We identified laws and regulations that are of significance in the context of the group and parent company by discussions with directors and by updating our understanding of the sector in which the group and parent company operates.
Laws and regulations of direct significance in the context of the group and parent company include The Companies Act 2006 and UK Tax legislation.
Audit response to risks identified
We considered the extent of compliance with these laws and regulations as part of our audit procedures on the related financial statement items including a review of group and parent company financial statement disclosures. We reviewed the parent company's records of breaches of laws and regulations, minutes of meetings and correspondence with relevant authorities to identify potential material misstatements arising. We discussed the parent company's policies and procedures for compliance with laws and regulations with members of management responsible for compliance.
During the planning meeting with the audit team, the engagement partner drew attention to the key areas which might involve non-compliance with laws and regulations or fraud. We enquired of management whether they were aware of any instances of non-compliance with laws and regulations or knowledge of any actual, suspected or alleged fraud. We addressed the risk of fraud through management override of controls by testing the appropriateness of journal entries and identifying any significant transactions that were unusual or outside the normal course of business. We assessed whether judgements made in making accounting estimates gave rise to a possible indication of management bias. At the completion stage of the audit, the engagement partner’s review included ensuring that the team had approached their work with appropriate professional scepticism and thus the capacity to identify non-compliance with laws and regulations and fraud.
As group auditors, our assessment of matters relating to non-compliance with laws or regulations and fraud differed at group and component level according to their particular circumstances. Our communications included a request to identify instances of non-compliance with laws and regulations and fraud that could give rise to a material misstatement of the group financial statements in addition to our risk assessment.
There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.
A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.
Other matters which we are required to address
The financial statements of Launch Diagnostics Holdings Limited for the year ended 31 December 2024 were audited as a single company only and not on a consolidated basis, therefore, no group audit opinion was expressed on them. We have obtained sufficient, appropriate audit evidence that the opening balances do not contain a misstatement that materially impact the current period financial statements.
Use of our report
This report is made solely to the parent company’s members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the parent company’s members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the parent company and the parent company’s members as a body, for our audit work, for this report, or for the opinions we have formed.
As permitted by section 408 of the Companies Act 2006, the company has not presented its own profit and loss account and related notes. The company’s loss for the year was £1,908,082 (2024 - £4,492,754 profit).
Launch Diagnostics Holdings Limited (“the company”) is a private company limited by shares incorporated in England and Wales. The registered office is Lakeview West, Crossways Business Park, Galleon Boulevard, Dartford, Kent, DA2 6QE.
The group consists of Launch Diagnostics Holdings Limited and all of its subsidiaries.
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.
The company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements for parent company information presented within the consolidated financial statements:
Section 7 ‘Statement of Cash Flows’: Presentation of a statement of cash flow and related notes and disclosures;
Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instrument Issues: Interest income/expense and net gains/losses for financial instruments not measured at fair value; basis of determining fair values; details of collateral, loan defaults or breaches, details of hedges, hedging fair value changes recognised in profit or loss and in other comprehensive income;
Section 26 ‘Share based Payment’: Share-based payment expense charged to profit or loss, reconciliation of opening and closing number and weighted average exercise price of share options, how the fair value of options granted was measured, measurement and carrying amount of liabilities for cash-settled share-based payments, explanation of modifications to arrangements;
Section 33 ‘Related Party Disclosures’: Compensation for key management personnel.
The group financial statements incorporate those of Launch Diagnostics Holdings Limited and all of its subsidiaries (ie entities that the group controls through its power to govern the financial and operating policies so as to obtain economic benefits). The results of subsidiaries acquired or sold are consolidated for the periods from or to the date on which control passed. Control is the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities.
All financial statements are made up to 31 December 2025. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.
All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.
At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The directors have reviewed budgets and cash flow forecasts to determine its ability to meet debts as and when they fall due. In preparing these forecasts, the directors have considered potential timetable delays and risks associated with uncertainty in the economy. As a result of this assessment, the directors have adopted the going concern basis of accounting for the preparation of these financial statements.
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the profit and loss account.
At each reporting period end date, the group reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.
Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.
Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.
The group has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the group's balance sheet when the group becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset and the net amounts presented in the financial statements when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets, which include debtors, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.
Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.
Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.
Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the group transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the group after deducting all of its liabilities.
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
Other financial liabilities, including debt instruments that do not meet the definition of a basic financial instrument, are measured at fair value through profit or loss.
Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.
Financial liabilities are derecognised when the group's contractual obligations expire or are discharged or cancelled.
Equity instruments issued by the group are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the group.
The tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the black scholes model. If material, the fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. The corresponding credit is recognised within other reserves as a capital contribution where the awards are granted by a parent undertaking and the Group has no obligation to settle the awards.
Leases are classified as hire purchase agreements whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under hire purchase agreements are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to the profit and loss account so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
In the application of the group’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
An analysis of the group's turnover is as follows:
The average monthly number of persons (including directors) employed by the group and company during the year was:
Their aggregate remuneration comprised:
The directors received remuneration totalling £299,180 (2024: £nil). This amount was paid by the subsidiary in the year. The remuneration paid to the highest paid director was £143,777 (2024: £nil).
i. Launch Diagnostics France SAS:
On 11 September 2025, Launch Diagnostics France SAS was sold to Duomed Holding France SAS and ceased to be a subsidiary of Launch Diagnostics Holdings Limited. Although the operations of Launch France continued under its new ownership, the disposal represented the Group's exit from that component of the business and the results of Launch Diagnostics France SAS have therefore been presented as discontinued operations up to the date of disposal. The group has recognised a loss of £375,651 on the sale of this subsidiary.
ii. Launch Diagnostics Deutschland GmbH:
On 26 June 2025, a resolution was passed to dissolve Launch Diagnostics Deutschland GmbH with immediate effect. The entity entered into liquidation following publication of the dissolution in the German Commercial Register on 4 August 2025. At the reporting date, the liquidation process remained ongoing and the entity had not yet been deregistered.
In the opinion of the directors, the aggregate value of the company's investment in subsidiary undertakings is not less than the amount included in the balance sheet.
Details of the company's subsidiaries at 31 December 2025 are as follows:
The principal activities of Launch Diagnostics Limited are centred around the provision of diagnostic reagents and hospital instrumentation in the United Kingdom. Its registered address is Lakeview West, Crossways Business park, Galleon Boulevard, Dartford, Kent, DA2 6QE.
The principal activities of Launch Diagnostics Deutschland GmbH was the provision of diagnostic reagents and hospital instrumentation in Germany. The company entered into liquidation on 4 August 2025. At the date of the approval of the financial statements liquidation has not yet concluded. Please see note 11 for further details. Its registered address is Amelia Mary Earhart Straße 8 c/o Youco24 Business Center, 60549, Frankfurt, Germany.
The actual charge/(credit) for the year can be reconciled to the expected charge/(credit) for the year based on the profit or loss and the standard rate of tax as follows:
Goodwill represents the excess of the cost of acquisition over the fair value of net assets of the business acquired. Goodwill is amortised through the profit and loss account in equal instalments over its estimated useful life of 10 years.
A review for impairment is carried out to establish whether events or changes in circumstances might result in the carrying amount being irrecoverable.
Short term assets include amounts in respect of assets held on hire purchase (and leased to customers) with a net book value of £34,151 (2024: £169,420). The depreciation charge for the year in relation to these amounted to £135,269 (2024: £190,187).
Amounts due from group undertakings are unsecured and repayable on demand. The balance comprises both interest‑free amounts and amounts accruing interest at Bank of England base rate plus 3%.
Amounts due to group undertakings are interest free, unsecured and repayable on demand.
Net obligations under hire purchase contracts are secured by fixed charges on the assets concerned.
Deferred tax assets and liabilities are offset where the group or company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:
The group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the group in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund. The outstanding pension liability at the year end was £20,597 (2024: £nil).
Included within other reserves is £32,833 (2024: £73,794) which relates to a foreign exchange reserve. The foreign exchange adjustment reserve represents foreign exchange differences arising on translation and consolidation of the overseas subsidiaries.
At the reporting end date the group had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:
The group has taken advantage of the exemption to disclose related party transactions with companies that are wholly owned within the group. The balances outstanding at the year end are disclosed in Notes 18 and 19.